Wednesday, November 08, 2017 4:52:50 PM
It has been a truly exciting journey to catch up with science, to analyze through clinical results from the company and the comments from other sources (bio columnists, scientists etc.) and to track insider trading around Oncosec. I basically re-update my limited knowledge about biology and sure have a deeper understanding over immunology and targeted therapy as well.
This is the era of targeted therapy and gene therapy. Immune checkpoint inhibitor, TRK inhibitor and CAR-T are the future. Oncs has established itself in a promising combinatorial niche, and has the potential to adapt its platform to more general and complicated gene therapy setups.
In terms of the mistrust over Dan, I understand that people judge based on history, but I believe in impartial analysis rather than conspiracy theory. Given his previous engagement with Merck for many years and over different setups. I believe the unexpected appointment demonstrates clear confidence and heralds accelerated deal making with Merck and interaction with FDA if PISCES confirms robust results. Also the fact that Punit and Avtar are still holding positions in the company at least should provide some checks and balances.
Let's wait in patience for the next leg and continue to watch and learn. In the meanwhile, it's good to have contrarians here so that we don't get overrun by overhyping.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM